Sensus Healthcare (SRTS) Q3 2024 earnings summary

Executive summary

• Revenues for Q3 2024 rose 127% year-over-year to $8.8 million, driven by strong SRT system sales and major agreements, including with Platinum Dermatology Partners.

• Net income for Q3 2024 was $1.2 million ($0.07 per diluted share), reversing a net loss of $1.5 million in Q3 2023.

• Adjusted EBITDA for Q3 2024 was $1.6 million, a $3.3 million improvement year-over-year.

• The Fair Deal Agreement, a shared revenue model, is gaining traction and is expected to generate significant recurring revenue starting in 2025, with over 50 IG-SRT systems expected to be signed by year-end.

• Ended Q3 2024 with $22.6 million in cash and no outstanding debt.

Financial highlights

• Q3 2024 revenues reached $8.8 million, up 127% from $3.9 million in Q3 2023; nine-month 2024 revenues were $28.7 million, up 143% year-over-year.

• Gross profit for Q3 2024 was $5.2 million (59.3% margin), up from $2 million (51% margin) in Q3 2023; nine-month gross margin was 60.3%.

• Net income for the nine months ended September 30, 2024, was $5.1 million versus a $3.7 million loss in the prior year.

• Operating expenses for Q3 2024 were $3.7 million, nearly flat year-over-year; nine-month operating expenses decreased 10.7% to $11.1 million.

• Diluted EPS was $0.07 for Q3 2024 and $0.31 for the nine months ended September 30, 2024.

Outlook and guidance

• Recurring revenue from the Fair Deal Agreement is expected to begin in 2025, with significant volumes projected for the second half.

• Gross margin is expected to remain around 60% for Q4 2024.

• Management expects continued growth and increasing interest from large dermatology groups, with no specific shipment or agreement targets for 2025 provided.

• Liquidity, cash flow from operations, and credit capacity are considered sufficient for the next 12 months.

• Inflationary pressures are being monitored, with proactive inventory management to mitigate cost impacts.